Mission to the Edge of Space and Supersonic freefall.

Red Bull Stratos, a mission to the edge of space, will attempt to transcend human limits that have existed for 50 years. Supported by a team of experts Felix Baumgartner plans to ascend to 120,000 feet in a stratospheric balloon and make a freefall jump rushing toward earth at supersonic speeds before parachuting to the ground. His attempt to dare atmospheric limits holds the potential to provide valuable medical and scientific research data for future pioneers.

The Red Bull Stratos team brings together the world's leading minds in aerospace medicine, engineering, pressure suit development, capsule creation and balloon fabrication. It includes retired United States Air Force Colonel Joseph Kittinger, who holds three of the records Felix will strive to break.

Joe's record jump from 102,800 ft in 1960 was during a time when no one knew if a human could survive a jump from the edge of space. Joe was a Captain in the U.S. Air Force and had already taken a balloon to 97,000 feet in Project ManHigh and survived a drogue mishap during a jump from 76,400 feet in Excelsior I. The Excelsior III mission was his 33rd parachute
jump.

Although researching extremes was part of the program's goals, setting records wasn't the mission's purpose. Joe ascended in helium balloon launched from the back of a truck. He wore a pressurized suit on the way up in an open, unpressurized gondola. Scientific data captured from Joe's jump was shared with U.S. research personnel for development of the space program. Today Felix and his specialized team hope to take what was learned from Joe's jumps more than 50 years ago and press forward to test the edge of the human envelope.

One of the primary ways that the United States Food and Drug Administration monitors the safety of marketed drugs is the collection and analysis of reported adverse events (an event that was not the intended outcome of the prescribed drug and has a negative impact on health) through the Adverse Events Reporting System (AERS). These reports are submitted by physicians, healthcare consumers, lawyers amongst others, and then the FDA scientific staff will assess these events in the context of other databases to determine if a particular safety concern is associated, and possibly caused by, exposure to a particular drug. Since this is a public database and useful to prescribers and patients alike to know if "has what I'm experiencing been described in patients taking this drug before?" DrugCite has created a more friendly interface to answer that question. Use of this data should in no way be confused with the FDA's rigorous process of evaluating the potential link of adverse events to drugs as causal but merely represents a portal into what is currently being reported to the Agency.

The leading source for trustworthy and timely health and medical news and information. Providing credible health information, supportive community, and educational services by blending award-winning expertise in content, community services, expert commentary, and medical review.